Dahlia Landa, MD
Allergy & Immunology · Bronx, NYNPI 1922276781
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,982 of the $10,135 with a category attached, or 68.9%. 29 manufacturers reported payments, led by Sanofi at 29.9% of the total. 2025 is the largest year on record at $3,711, 5.1 times the $734 reported in 2019.
Across 376 payments — averaging $26.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$3K
- ARS Pharmaceuticals Operations, Inc.$2K
- AstraZeneca$1K
- GSK$979
- Novartis$471
- Optinose US, Inc.$443
- plus $2K from 23 others
What the payments were for
- Consulting fees$1,09511%
- Speaking & faculty fees$2,00020%
- Food & beverage$6,98269%
- Education$581%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 77 | $3,033 |
| ARS Pharmaceuticals Operations, Inc. | 13 | $2,140 |
| AstraZeneca | 51 | $1,070 |
| GSK | 54 | $979 |
| Novartis | 34 | $471 |
| Optinose US, Inc. | 31 | $443 |
| Genentech USA, Inc. | 39 | $408 |
| Regeneron Healthcare Solutions, Inc. | 17 | $401 |
| Kaleo, Inc. | 14 | $265 |
| Amgen | 7 | $144 |
| Alk-abello, Inc | 4 | $118 |
| Phadia US Inc. | 5 | $95 |
| Grifols USA, LLC | 5 | $77 |
| AbbVie | 4 | $68 |
| Teva Pharmaceuticals USA, Inc. | 3 | $63 |
| CSL Behring | 3 | $58 |
| Paratek Pharmaceuticals, Inc. | 2 | $49 |
| Medtronic | 2 | $42 |
| Neurent Medical Limited | 1 | $28 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Incyte Corporation | 1 | $25 |
| Acclarent, Inc | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Merck | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Stryker | 1 | $16 |
| Pfizer | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Hikma Pharmaceuticals USA | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,135 in reported general payments places this provider in the 75th percentile of 320 allergy & immunology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 97 | $393,233 |
| Epinephrine | 145 | $39,597 |
| XolairOmalizumab | 13 | $33,936 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $7,782 |
| Azelastine Hcl | 138 | $1,615 |
| Fluticasone Propionate | 96 | $764 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $699 |
| Montelukast Sodium | 53 | $419 |
| Levocetirizine Dihydrochloride | 15 | $127 |
| Triamcinolone Acetonide | 16 | $110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USAEpinephrine | $12 | $39,597145 claims |
| GSKBreo Ellipta | $979 | $7,78211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 320 allergy & immunology providers in New York.
Other allergy & immunology in Bronx
- Tania ElliottBronx$43K
- Golda HudesBronx$29K
- Ujwala KazaNew York$1.1M
- Syed MustafaRochester$948K
- Robert SporterNew York$946K
- Gregory PuglisiPlainview$813K
- Stanley GoldsteinRockville Centre$643K
- Robert TamayevRego Park$321K
- Richard InselNew York$269K
- Payel GuptaBrooklyn$256K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.